Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation

Christine N. Duncan*, Ruta Brazauskas, Jiaxing Huang, Bronwen E. Shaw, Navneet S. Majhail, Bipin N. Savani, Mary E.D. Flowers, Minoo Battiwalla, Kristen Beebe, Andrew C. Dietz, Christopher C. Dvorak, Roger Giller, David A. Jacobsohn, Morris Kletzel, Paul L. Martin, Eneida R. Nemecek, Brandon Nuechterlein, Julie An Talano, Michael A. Pulsipher, K. Scott Baker

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 97 months (range 24–230). 4.2% of survivors experienced at least one of the primary outcomes including coronary artery disease (0.2%), cerebrovascular accident (0.6%), cardiomyopathy (3%), and cardiac-related death (0.5%). Patients who received anthracycline chemotherapy (HR 4.67, p = 0.036) or cranial or chest radiation (HR 5.58, p < 0.0001; HR 2.18, p = 0.0087) were at increased risk for developing one of the primary outcomes. Dyslipidemia was diagnosed in 18% of survivors. Pre-transplant anthracycline (HR 1.74, p < 0.0001) and chest radiation (HR 1.34, p = 0.0371) were risk factors for dyslipidemia. Overweight/obese body mass status was present in 63% of patients at baseline, 65% at 2 years, and 52% at most recent evaluation. Diabetes was diagnosed in 7% of subjects. In conclusion, severe cardiovascular complications were infrequently reported. The incidence of risk factors including obesity and dyslipidemia were significant and will likely increase the risk of cardiovascular disease over time in transplant survivors.

Original languageEnglish (US)
Pages (from-to)1278-1287
Number of pages10
JournalBone Marrow Transplantation
Volume53
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Cell Transplantation
Dyslipidemias
Survivors
Anthracyclines
Pediatrics
Morbidity
Transplants
Mortality
Thorax
Radiation
Hematologic Neoplasms
Cardiomyopathies
Coronary Artery Disease
Cardiovascular Diseases
Obesity
Bone Marrow
Stroke
Drug Therapy
Incidence
Research

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Duncan, C. N., Brazauskas, R., Huang, J., Shaw, B. E., Majhail, N. S., Savani, B. N., ... Baker, K. S. (2018). Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 53(10), 1278-1287. https://doi.org/10.1038/s41409-018-0155-z
Duncan, Christine N. ; Brazauskas, Ruta ; Huang, Jiaxing ; Shaw, Bronwen E. ; Majhail, Navneet S. ; Savani, Bipin N. ; Flowers, Mary E.D. ; Battiwalla, Minoo ; Beebe, Kristen ; Dietz, Andrew C. ; Dvorak, Christopher C. ; Giller, Roger ; Jacobsohn, David A. ; Kletzel, Morris ; Martin, Paul L. ; Nemecek, Eneida R. ; Nuechterlein, Brandon ; Talano, Julie An ; Pulsipher, Michael A. ; Baker, K. Scott. / Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. In: Bone Marrow Transplantation. 2018 ; Vol. 53, No. 10. pp. 1278-1287.
@article{921e941813db4fb9a1544fa1d295d95d,
title = "Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation",
abstract = "We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 97 months (range 24–230). 4.2{\%} of survivors experienced at least one of the primary outcomes including coronary artery disease (0.2{\%}), cerebrovascular accident (0.6{\%}), cardiomyopathy (3{\%}), and cardiac-related death (0.5{\%}). Patients who received anthracycline chemotherapy (HR 4.67, p = 0.036) or cranial or chest radiation (HR 5.58, p < 0.0001; HR 2.18, p = 0.0087) were at increased risk for developing one of the primary outcomes. Dyslipidemia was diagnosed in 18{\%} of survivors. Pre-transplant anthracycline (HR 1.74, p < 0.0001) and chest radiation (HR 1.34, p = 0.0371) were risk factors for dyslipidemia. Overweight/obese body mass status was present in 63{\%} of patients at baseline, 65{\%} at 2 years, and 52{\%} at most recent evaluation. Diabetes was diagnosed in 7{\%} of subjects. In conclusion, severe cardiovascular complications were infrequently reported. The incidence of risk factors including obesity and dyslipidemia were significant and will likely increase the risk of cardiovascular disease over time in transplant survivors.",
author = "Duncan, {Christine N.} and Ruta Brazauskas and Jiaxing Huang and Shaw, {Bronwen E.} and Majhail, {Navneet S.} and Savani, {Bipin N.} and Flowers, {Mary E.D.} and Minoo Battiwalla and Kristen Beebe and Dietz, {Andrew C.} and Dvorak, {Christopher C.} and Roger Giller and Jacobsohn, {David A.} and Morris Kletzel and Martin, {Paul L.} and Nemecek, {Eneida R.} and Brandon Nuechterlein and Talano, {Julie An} and Pulsipher, {Michael A.} and Baker, {K. Scott}",
year = "2018",
month = "10",
day = "1",
doi = "10.1038/s41409-018-0155-z",
language = "English (US)",
volume = "53",
pages = "1278--1287",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

Duncan, CN, Brazauskas, R, Huang, J, Shaw, BE, Majhail, NS, Savani, BN, Flowers, MED, Battiwalla, M, Beebe, K, Dietz, AC, Dvorak, CC, Giller, R, Jacobsohn, DA, Kletzel, M, Martin, PL, Nemecek, ER, Nuechterlein, B, Talano, JA, Pulsipher, MA & Baker, KS 2018, 'Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation', Bone Marrow Transplantation, vol. 53, no. 10, pp. 1278-1287. https://doi.org/10.1038/s41409-018-0155-z

Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. / Duncan, Christine N.; Brazauskas, Ruta; Huang, Jiaxing; Shaw, Bronwen E.; Majhail, Navneet S.; Savani, Bipin N.; Flowers, Mary E.D.; Battiwalla, Minoo; Beebe, Kristen; Dietz, Andrew C.; Dvorak, Christopher C.; Giller, Roger; Jacobsohn, David A.; Kletzel, Morris; Martin, Paul L.; Nemecek, Eneida R.; Nuechterlein, Brandon; Talano, Julie An; Pulsipher, Michael A.; Baker, K. Scott.

In: Bone Marrow Transplantation, Vol. 53, No. 10, 01.10.2018, p. 1278-1287.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation

AU - Duncan, Christine N.

AU - Brazauskas, Ruta

AU - Huang, Jiaxing

AU - Shaw, Bronwen E.

AU - Majhail, Navneet S.

AU - Savani, Bipin N.

AU - Flowers, Mary E.D.

AU - Battiwalla, Minoo

AU - Beebe, Kristen

AU - Dietz, Andrew C.

AU - Dvorak, Christopher C.

AU - Giller, Roger

AU - Jacobsohn, David A.

AU - Kletzel, Morris

AU - Martin, Paul L.

AU - Nemecek, Eneida R.

AU - Nuechterlein, Brandon

AU - Talano, Julie An

AU - Pulsipher, Michael A.

AU - Baker, K. Scott

PY - 2018/10/1

Y1 - 2018/10/1

N2 - We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 97 months (range 24–230). 4.2% of survivors experienced at least one of the primary outcomes including coronary artery disease (0.2%), cerebrovascular accident (0.6%), cardiomyopathy (3%), and cardiac-related death (0.5%). Patients who received anthracycline chemotherapy (HR 4.67, p = 0.036) or cranial or chest radiation (HR 5.58, p < 0.0001; HR 2.18, p = 0.0087) were at increased risk for developing one of the primary outcomes. Dyslipidemia was diagnosed in 18% of survivors. Pre-transplant anthracycline (HR 1.74, p < 0.0001) and chest radiation (HR 1.34, p = 0.0371) were risk factors for dyslipidemia. Overweight/obese body mass status was present in 63% of patients at baseline, 65% at 2 years, and 52% at most recent evaluation. Diabetes was diagnosed in 7% of subjects. In conclusion, severe cardiovascular complications were infrequently reported. The incidence of risk factors including obesity and dyslipidemia were significant and will likely increase the risk of cardiovascular disease over time in transplant survivors.

AB - We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 97 months (range 24–230). 4.2% of survivors experienced at least one of the primary outcomes including coronary artery disease (0.2%), cerebrovascular accident (0.6%), cardiomyopathy (3%), and cardiac-related death (0.5%). Patients who received anthracycline chemotherapy (HR 4.67, p = 0.036) or cranial or chest radiation (HR 5.58, p < 0.0001; HR 2.18, p = 0.0087) were at increased risk for developing one of the primary outcomes. Dyslipidemia was diagnosed in 18% of survivors. Pre-transplant anthracycline (HR 1.74, p < 0.0001) and chest radiation (HR 1.34, p = 0.0371) were risk factors for dyslipidemia. Overweight/obese body mass status was present in 63% of patients at baseline, 65% at 2 years, and 52% at most recent evaluation. Diabetes was diagnosed in 7% of subjects. In conclusion, severe cardiovascular complications were infrequently reported. The incidence of risk factors including obesity and dyslipidemia were significant and will likely increase the risk of cardiovascular disease over time in transplant survivors.

UR - http://www.scopus.com/inward/record.url?scp=85044469262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044469262&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0155-z

DO - 10.1038/s41409-018-0155-z

M3 - Article

C2 - 29581480

AN - SCOPUS:85044469262

VL - 53

SP - 1278

EP - 1287

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -